Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan in Advanced Sarcomas
NCT00509860Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2003
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in sarcoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Efficacy of irinotecan at 12 weeks and Toxicity profile. Started Mar 2003; status: completed.
02
Drugs
irinotecan
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT00509860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00509860.